Case Studies

Case Studies

Semi-mechanistic Platform Model for Checkpoint Inhibitors

A model platform that captures the individual animal responses to two checkpoint therapeutic antibodies
anti-PD-1 and anti-CTLA-4
in the CT26 syngeneic tumor model

QSP Model of a Cytokine mRNA Immunotherapy

A quantitative systems pharmacology platform that captures the observed preclinical tumor responses and allows for systemic predictions under a variety of conditions

QSP Model for Alzheimer's Disease

Quantitative Systems Pharmacology model of amyloid beta and plaque dynamics in Alzheimer’s Disease upon treatment with anti-amyloid beta and BACE inhibitor drugs

Inferring target occupancy

A semi-mechanistic PKRO model to capture Pembro phase I PK data and help predict PD-1 target RO

First-in-Human Dose Predictions

A modRNA as a Lipid Nanoparticle to treat Crigler-Najjar Syndrome Type 1

Clinical Candidate Selection

Immuno-modulation in Chronic Inflammation

Phase-1 Interim Analysis

Immuno-modulation in Chronic Inflammation

Early Feasibility Assessment

Optimizing Design of a Bispecific Therapeutic Antibody using QSP

Predicting Optimal Drug Parameters and Doses

QSP approaches accelerate lead generation and optimization of a PD-1 x TIM-3 therapeutic in I/O

Antibody-Drug Conjugate (ADC) Design

Computational Exploration of ADC PK